Committed to innovation

and growth

Roland Diggelmann, COO Roche Diagnostics Paris, 18 March 2015

2014 Group results

Diagnostics

Business model & strategy

2014 overview

Building a leading sequencing solution

Outlook

2

2014: Targets achieved

3

Targets for 2014 FY 2014

Group sales Low to mid-single digit growth1 +5%

Core EPS Ahead of sales growth1

+5%

+7% excl. one-time

US Pharma fee2

Dividend Further increase dividend3 CHF 8.00

+3%

1 At constant exchange rates 2 One-time double charge of CHF 202m for the US Branded Prescription Drug fee in 2014, following final regulations issued by the US

Internal Revenue Service which advanced the timing of recording the liability 3 2014 dividend as proposed by the Board of Directors

First take on Swiss National Bank`s decision

4

On January 15, the Swiss National Bank (SNB) announced its decision to unpeg

the Swiss franc from the Euro

Natural hedge of the underlying business:

• 18% of operating costs in Switzerland

• US, Europe, Japan and China with complete value chain

• Interest expenses predominantly paid in USD

• 2015 dividend payout for March converted prior to SNB decision

2014: Solid sales growth

5

2014 2013

CHFbn CHFbn CHF CER

Pharmaceuticals Division 36.7 36.3 1 4

Diagnostics Division 10.8 10.5 3 6

Roche Group 47.5 46.8 1 5

Change in %

CER=Constant Exchange Rates

2014: Continued sales growth for 4 years

6

0% 0% 1%

4%

2%

6%

4%

6% 6%

4%

8%

7%

5%

4%

5%

6%

0%

2%

4%

6%

8%

10%

Q1

11

Q2

11

Q3

11

Q4

11

Q1

12

Q2

12

Q3

12

Q4

12

Q1

13

Q2

13

Q3

13

Q4

13

Q1

14

Q2

14

Q3

14

Q4

14

All growth rates at Constant Exchange Rates (CER)

2014: Group core operating profit & margin

remains at high levels

7

16.6

15.1

17.2 17.9 17.6

34.9% 35.6% 37.7% 38.3%

37.2%

2010 2011 2012 2013 2014

+3% at CER (+5%*) % of sales

CHFbn

(37.6%*)

CER=Constant Exchange Rates

* Excluding one-time double charge for the US Branded Prescription Drug fee in 2014

2014: Dividend and payout ratio further increased

8 1 compound annual growth rate

8.00

31.9 34.5

38.8

44.8

48.6

51.6

55.3

54.5

54.7 56.0

0.00

1.00

2.00

3.00

4.00

5.00

6.00

7.00

8.00

9.00

10.00

1990 1992 1994 1996 1998 2000 2002 2004 2006 2008 2010 2012 2014

Dividend payout ratio (%) CHF

2014 payout ratio: 56.0%

Payout ratio calculated as dividend per share divided by core earnings per share (diluted); 2014 dividend as proposed by the Board of

Directors; Note: For 1995, a special dividend was paid out to mark F. Hoffmann-La Roche’s 100th anniversary in 1996

2014 Group results

Diagnostics

Business model & strategy

2014 overview

Building a leading sequencing solution

Outlook

9

In-Vitro Diagnostics market overview

Large and growing market; Roche is market leader

10

Source: Roche Analysis, Company reports for 2013 validated by an independent IVD consultancy

Market share

20%

11%

10%

8% 7% 3%

40%

Roche

Abbott

Siemens

J&J Danaher

Biomerieux

Others

Market size

USD 52 bn

Molecular Diagnostics

Professional Diagnostics

Tissue Diagnostics

Diabetes Monitoring

Our business model

Place instruments to generate recurring revenues through reagent usage

11

Closed

Systems

best instrument technology broadest menu

Our strategy

Differentiation through innovation in testing efficiency and medical value

12

2012 2020

Medical

Value

Drivers of

competitive differentiation

Testing

Efficiency

2014 Group results

Diagnostics

Business model & strategy

2014 overview

Building a leading sequencing solution

Outlook

13

2014: Diagnostics Division sales

Growth driven by Professional Diagnostics

14

2014 2013

CHFm CHFm CHF CER

Diagnostics Division 10,766 10,476 3 6

Professional Diagnostics 6,045 5,772 5 8

Diabetes Care 2,392 2,459 -3 1

Molecular Diagnostics 1,613 1,580 2 6

Tissue Diagnostics 716 665 8 10

Change in %

Underlying growth of Molecular Diagnostics excluding Sequencing Solutions: +8%

CER=Constant Exchange Rates

North America

+4%

25% of divisional sales

Latin America

+13%

7% of divisional sales

Japan

0%

4% of divisional sales EMEA1

+4%

45% of divisional sales

2014: Diagnostics regional sales

Growth driven by APAC and EMEA

Asia Pacific

+15%

19% of divisional sales

15

16% growth in E7 countries2

1Europe, Middle East and Africa; 2Brazil, China, India, Mexico, Russia, South Korea, Turkey All growth rates at constant exchange rates

2014: Diagnostics Division

Profit growth in line with sales excl. PSI*

16 CER=Constant Exchange Rates

* PSI: 2013 past service income of CHF 67m; VAT: 2013 one-time VAT refund of CHF 45m

CHFm % sales

Sales 10,766 100.0

Royalties & other op. inc. 131 1.2

Cost of sales -4,790 -44.4

M & D -2,462 -22.9

R & D -1,037 -9.6

G & A -512 -4.8

Core operating profit 2,096 19.5

2014 2014 vs. 2013

CER growth

-4% in CHF

6%

2%

9%

4%

3%

21%

2%

Admin: +6%

Excl. PSI*: +5%

Excl. PSI*: +5%

and VAT*: +8%

Excl. VAT*: +8%Excl. VAT*: +8%

2014: Diagnostics

Growth driven by Professional Diagnostics

+1%

• Virology (+7%) incl. HPV (+48%) • Launch of cobas 6800/8800 systems with assays for blood

screening and virology

• Accu-Chek Aviva/Performa (+7%) and Mobile (+19%)

• Advanced staining portfolio (+9%) and companion

diagnostics (+27%)

1 Underlying growth of Molecular Diagnostics excluding Sequencing Solutions: +8%

CER=Constant Exchange Rates; EMEA=Europe, Middle East and Africa

CER growth

1

+8%

+6%

+10%

• Continued double digit growth in immunodiagnostics (+13%)

• Further expansion of leading menu

0 1 2 3 4 5 6

Tissue Dia

Molecular

Dia

Diabetes

Care

Professional

Dia

EMEA

North America

RoW

Sales

CHFbn

17

Serum work area (42% of sales)*

Growing strongly in all regions

18

+5%

+8%

+15%

+19%

+8%

+10%

EMEA

Asia-Pacific

North America

Japan

Latin America

*SWA: serum work area: clinical chemistry and immunodiagnostics

2013 2014

Integrated SWA* solution

– Immunodiagnostics (+13%)

– Clinical chemistry (+7%)

Invest for growth

New reagent manufacturing in China

• Reliable local supply and right

sizing of cost base

• Reagent formulation, filling and

packaging

– Packaging to begin in 2016

– Fully operational in 2018

2012 2022E 2017E

Other

Asia

RPD reagent volume

x2

19 RPD = Roche Professional Diagnostics

Roche Diagnostics Test Portfolio

Industry Leading Menu

20

Extend leading menu in women’s health

High prognostic value of preeclampsia blood test

21

Assay and claim extension

• Extends the applicability of the assay

from 3-5% of pregnancies to 20%

• Fully automated

• Test performed across entire cobas

analyzer platform series

* Hund, M., et al. (2014) BMC Pregnancy and Childbirth 14, 324;

Zeisler, H.,. et al. (2014) XX COGI World Congress 2014

*Preeclampsia can be ruled-out for 1 week after testing

Medium Hospitals

Large Hospitals

Reference Labs

High Throughput

Low Throughput

cobas® 6800

cobas® 4800

cobas® 8800

Molecular Diagnostics

Launch and implementation of cobas 6800/8800

• Advanced PCR automation

• Highest throughput (3x above closest

competitor)

• CE launch of blood screening and

virology assays

• Low to middle volume throughput

• Broadest menu incl HPV testing

22

Entering Molecular Point of Care Diagnostics

Acquisition of IQuum, launch of cobas Liat™ analyzer

23

Target market:

• ~CHF 350m, growing ~20% p.a.

Laboratory in a tube technology:

• Fast and easy to use

• CLIA waiver expected in 2015

Portfolio:

• Influenza A/B and Strep A test, CE marked and FDA cleared

• Plans to extend menu in:

– Respiratory Syncytial Virus tests

– MRSA and C-difficile

Liat™ Analyzer Liat™ tube

Point of Care: e.g. physician’s office, emergency rooms, ambulance, pharmacies; MRSA: methicillin resistant Staphilococcus aureus

2014 Group results

Diagnostics

Business model & strategy

2014 overview

Building a leading sequencing solution

Outlook

24

DNA testing market*: 10-year estimates

Next-generation sequencing (NGS) will be the

fastest-growing segment

DNA testing uses different

technologies which are complementary

in applications:

• Molecular (PCR):

– virology

– blood screening

– Oncology

– Infectious disease

• In situ hybridization (ISH)

– oncology

• Sequencing:

– Whole genome sequencing and

targeted sequencing

– Mutation detection

– Oncology

– Pre-natal, newborn

– Infectious disease

Roche is market leader in DNA testing Complement offering with leading sequencing solution

* Includes Lab developed tests; PCR: polymerase chain reaction; Sanger: oldest sequencing technology; ISH: in situ hybridization

Sequencing strategy

Building a leading sequencing solution

26

Grow through

disruptive

innovation

Sample

preparation

Testing

platform

Menu of

assays

Data

analysis Reporting

Developing complete sequencing solutions

Abvitro: Technology acquisition; Ariosa: Acquisition; Genia: Acquisition; Pacific Biosciences: Partnership; Bina: Acquisition; Foundation Medicine: Partnership

Sequencing menu: Non-invasive prenatal testing

Acquisition of Ariosa

27

Target market

• USD 400m sales worldwide in 2013, +30% pa

Technology

• Analyses fetal DNA with microarray technology

• Highly cost effective and accurate

• Screens for the risk of Down, Edwards and Patau

syndrome

Strategy

• Expand market access through kit distribution model

• Add test to Roche sequencing platform when available

HarmonyTM Prenatal Test

Digital analysis of selected

regions (DANSRTM) technology

2014 Group results

Diagnostics

Business model & strategy

2014 overview

Building a leading sequencing solution

Outlook

28

1 Business Areas. RPD: Roche Professional Diagnostics; RDC: Roche Diabetes Care; RMD: Roche Molecular Diagnostics;

RTD: Roche Tissue Diagnostics;

Key launches 2015

29

Area Product Market BA1

Instruments

/

Devices

Laboratory

cobas c 513 – dedicated HbA1C analyzer

cobas t 411– core lab coagulation analyzer

cobas 8100 V2 – Integrated pre- and post-analytical solution

cobas® 6800/8800 – Medium to High volume automated real-time PCR

VENTANA HE 600 – automated H&E staining platform

EU

EU

WW

US

WW

RPD

RPD

RPD

RMD

RTD

Diabetes

Care

Accu-Chek Active no-code– next-gen. bG meter, no coding of test strips

Accu-Chek Connect – bG meter with connectivity to smartphones, mobile

applications and cloud

WW

US

RDC

RDC

Point of Care CoaguChek® Pro II - professional system for PT and aPTT testing EU RPD

Tests

/

Assays

Blood

Screening cobas® 6800/8800 MPX – Multiplex Bloodscreening test US RMD

Infectious

Diseases

cobas® Liat Influenza A/B + RSV – POC detection

HTLV– human T-lymphotropic virus diagnostics test

US

EU

RMD

RPD

Virology

cobas® 6800/8800 HBV – Quantitative HBV viral load test

cobas® 4800 HIV-1 - Quantitative HIV viral load test

cobas® 4800 HCV – Quantitative HCV viral load test

cobas® 4800 HBV – Quantitative HBV viral load test

EU

EU

EU

EU

RMD

RMD

RMD

RMD

Genomics &

Oncology cobas® EGFR Test v2 - detection of EGFR in plasma EU RMD

Cardiac Cobas h 232 Troponin T – Point of Care test version of Elecsys cTNT-hs EU RPD

Outlook

Investing into future growth

• Continued strong growth in serum work area

• Focus on implementation of next generation platforms, e.g. cobas 6800/8800

• Continued investment into development of future sequencing solution

• Ongoing structural adjustments in Diabetes Care to adapt to continuing

challenging market environment

• Strengthen leading presence in emerging markets

30

Rituxan/MabThera RA

Neuroscience

6 NMEs

ocrelizumab

gantenerumab

Roche: A pipeline of differentiated products

Launched

Phase III

Phase II 10 NMEs + 9 AIs

Rituxan/MabThera

Xeloda

Herceptin

Perjeta

Kadcyla

Avastin

Gazyva/Gazyvaro

Tarceva

Zelboraf

Erivedge

Immunology/

Ophthalmology

Actemra/RoActemra

Lucentis

Xolair

Esbriet

Pulmozyme

lebrikizumab

lampalizumab3

etrolizumab2

anti-PDL1

taselisib1

venetoclax (Bcl2i)

cobimetinib4

pictilisib1

alectinib

31

Oncology

Neuroscience

Ophthalmology

Immunology

Oncology

3 AIs

1 Phase III decision pending; 2 FPI in 1H 2014; 3 FPI in 2H 2014; 4 Filed in combination with Zelboraf in metastatic melanoma

AI = Additional Indication; NME = New Molecular Entity

2015: Key late-stage news flow

32

Compound Indication Milestone

Regulatory

Avastin Cervical cancer EU approval

Lucentis Diabetic retinopathy US approval

alectinib ALK+ NSCLC US filing

Cobimetinib + Zelboraf 1L Melanoma US, EU approval

Phase III readouts*

Gazyva Front line aNHL Ph III GOYA (interim)

ocrelizumab Relapsing MS (RMS) Ph III OPERA I/II

ocrelizumab Primary progressive MS (PPMS) Ph III ORATORIO

Perjeta 2L HER2+ mBC Ph III PHEREXA

Kadcyla HER2+ gastric cancer Ph II/III GATSBY

Phase III starts

Anti-PDL1 Bladder Ph III

Anti-PDL1 Tumor type 1 Ph III

Anti-PDL1 Tumor type 2 Ph III

Anti-PDL1 Tumor type 3 Ph III

Etrolizumab Crohn`s disease Ph III

ACE910 Hemophilia A Ph III

taselisib (PI3K inhib) HR+/PI3Kmut BC Ph III SANDPIPER

Phase II readouts*

Anti-PDL1 2/3L NSCLC Ph II FIR, POPLAR, BIRCH

Anti-PDL1 Bladder Ph II

ipatasertib (AKT inhib) Gastric/prostate cancers Ph II A.MARTIN, JAGUAR

* Outcome studies are event driven, timelines may change

Roche Group development pipeline

33

Phase I

(33 NMEs + 11 AIs)

Raf & MEK dual inh solid tumors

venetoclax (Bcl-2) heme indications

ChK1 inh solid tum & lymphoma

Oncology Other disease areas

Status as of January 28, 2015

HER3 MAb solid tumors

MDM2 ant solid & hem tumors

New Molecular Entity (NME) Additional Indication (AI)

Oncology

Immunology

Infectious Diseases

CardioMetabolism

Neuroscience

Ophthalmology

Other

RG-No Roche Genentech managed

CHU Chugai managed

PD-L1 MAb+Zelboraf+/-cobimetinib m. melanoma

Steap 1 ADC prostate ca.

PD-L1 MAb+Avastin+chemo solid tumors

PD-L1 MAb solid tumors

PD-L1 MAb+cobimetinib solid tumors

venetoclax (Bcl-2)+ Gazyva CLL CLL

PD-L1 MAb+Tarceva NSCLC EGFR+

ERK inh solid tumors

CEA IL2v solid tumors

LSD1 inh AML

ADC solid tumors

MDM2 (4) IV prodrug AML

ADC ovarian ca

PD-L1 MAb+ipi/IFN solid tumors

OX40 MAb solid tumors

Lucentis sust. deliv. AMD/RVO/DME

PDE10A inh schizophrenia

Nav1.7 inh pain

VEGF-ANG2 MAb wAMD

TAAR1 ago schizophrenia

a-synuclein MAb Parkinson's Disease

mGlu5 PAM schizophrenia

SMN2 splicer spinal muscular atrophy

TLR7 agonist HBV RG7795

RG3645

RG7203

RG7893

aldosterone synth inh met. diseases RG7641

RG7716

RG7410

RG7935

RG7342

RG7800

HIF1 alpha LNA solid tumors

RG7304

RG7601

RG7741

RG7116

RG7388

RG7446

RG7450

RG7446

RG7446

RG7446

RG7601

RG7446

RG7842

RG7813

RG6016

RG7841

RG7775

RG7882

RG7446

RG7888

RG6061

CEA CD3 TCB solid tumors RG7802

CD40 iMAb+PD-L1 MAb solid tumors RG7876

MSLN PE cFP solid tumors RG7787

PD-L1 MAb+Gazyva lymphoma RG7446

- autoimmune diseases RG7880

autoimmune diseases RG7625

- infectious diseases RG7689

DBO β-lactamase inh bact. infections RG6080

TAUpS422 MAb Alzheimer’s RG7345

CSF-1R + PDL-1 MAb solid tumors RG7155

SERD (2) ER+(HER2-neg) mBC RG6047

IDO inh solid tumors RG6078

HER3/EGFR DAF+ cobi KRAS+ s. tumors RG7597

New Molecular Entity (NME)

Additional Indication (AI)

RG-No Roche Genentech managed

CHU Chugai managed

RG105 MabThera is branded as Rituxan in US and Japan

RG1569 Actemra is branded as RoActemra in EU

RG7159 Gazyva is branded as Gazyvaro in EU

Oncology

Immunology

Infectious Diseases

CardioMetabolism

Neuroscience

Ophthalmology

Other

Roche Group development pipeline

34

Phase II

(23 NMEs + 12 Als)

Phase III

(9 NMEs + 21 Als)

Registration

(1 NME + 4 Als)

1 US only : FDA submission decision pending

2 Approved in US, submitted in EU

3 Submitted in US

crenezumab Alzheimer’s RG7412

lampalizumab (factor D) geo. atrophy RG7417

Lucentis diabetic retinopathy RG36453

Avastin recurrent cervical cancer RG4352

Perjeta HER2+ BC neoadj RG12732

cobimetinib + Zelboraf m. melanoma RG7421

MabThera SC CLL RG105

Status as of January 28, 2015

Avastin glioblastoma 1st line RG4351

Avastin NSCLC adj RG435

Kadcyla +/- Perjeta HER2+ mBC 1st l RG3502

ocrelizumab RMS RG1594

Gazyva DLBCL 1st line RG7159

ocrelizumab PPMS RG1594

Actemra large-vessel vasculitis CHU

lebrikizumab severe asthma RG3637

Zelboraf melanoma adj RG7204

Perjeta HER2+ gastric cancer 1st line RG1273

Actemra giant cell arteritis RG1569

etrolizumab ulcerative colitis RG7413

Perjeta HER2+ mBC 2nd line RG1273

alectinib (ALK inhibitor) NSCLC RG7853

Gazyva iNHL rituximab refractory RG7159

Gazyva follicular lymphoma 1st line RG7159

venetoclax (Bcl-2) + Rit. CLL rel/ref RG7601

Kadcyla HER2+ gastric cancer 2nd line RG3502

gantenerumab Alzheimer’s RG1450

PD-L1 MAb NSCLC 2nd line RG7446

Kadcyla + Perjeta HER2+ BC adj RG3502

Kadcyla + Perjeta HER2+ BC neoadj RG3502

IL-6R MAb neuromyelitis optica CHU

Perjeta HER2+ BC adj RG1273

Kadcyla HER2+ BC adj RG3502

venetoclax+Gazyva (Bcl-2) CLL 1st line RG7601

Avastin ovarian cancer 1st line RG4351

Avastin rel. ovarian ca. Pt-sensitive RG4351

PD-L1 MAb bladder cancer 2nd line RG7446

bitopertin obsessive compulsive dis. RG1678

danoprevir HCV RG7227

basimglurant (mGlu5 NAM) TRD RG7090

MAO-B inh Alzheimer’s RG1577

Actemra systemic sclerosis RG1569

polatuzumab vedotin (CD79bADC) hem tumors RG7596

V1 receptor antag autism RG7314

ipatasertib (AKT inh) solid tumors RG7440

lebrikizumab idiopathic pulmonary fibrosis RG3637

LptD antibiotic antibacterial

RG7929

venetoclax (Bcl-2) C LL rel/refract 17pdel RG7601

PD-L1 MAb bladder cancer 1/2l RG7446

Flu A MAb influenza RG7745

IL-31R MAb atopic dermatitis CHU

FIXa /FX bispecific MAb hemophilia A RG6013

PD-L1 MAb NSCLC 2nd/3rd line RG7446

GABRA5 NAM Down Syndrome RG1662

ADC lifastuzumab vedotin (NaPi2bADC)Pt-resist. OC RG7599

PD-L1 MAb + Avastin RCC RG7446

CSF-1R MAb PVNS/solid tumors RG7155

taselisib (mutant-selective) solid tumors RG7604

venetoclax (Bcl-2) DLBCL RG7601

Ang2-VEGF MAb colorectal cancer RG7221

setrobuvir HCV RG7790

glypican-3 MAb liver cancer RG7686

GIP/GLP-1 dual ago type 2 diabetes RG7697

Esbriet SSc – interstitial lung disease RG6062

cobimetinib TNBC RG7421

Avastin+Tarceva EGFR mut+ NSCLC RG435

venetoclax (Bcl-2)+ Rituxan rel/ref FL RG7601

pictilisib pictilisib solid tumors RG7321

SERD ER+(HER2-neg) mBC RG6046

URAT 1 inh gout CHU

RG7929

Kadcyla HER2+ NSCLC RG3502

lebrikizumab IPF RG3637

NME submissions and their additional indications

Projects currently in phase 2 and 3

35

Unless stated otherwise, submissions are planned to occur in US and EU

* lead market China

Neuroscience

Ophthalmology

Other

NME

Oncology

Immunology

Infectious Diseases

CardioMetabolism

bitopertin (RG1678)

obsessive compulsive dis.

ocrelizumab (RG1594) RMS

cobimetinib (MEK inh) combo Zelboraf

met melanoma

danoprevir* (RG7227) HCV

basimglurant (RG7090) depression

crenezumab (RG7412) Alzheimer‘s

gantenerumab (RG1450) Alzheimer‘s

V1 receptor antag (RG7314) autism

glypican-3 Mab (RG7686) liver cancer

lampalizumab anti-factor D (RG7417) geo atrophy

lebrikizumab (RG3637) severe asthma

etrolizumab (RG7413) ulcerative colitis

2014 2015 2017 and beyond

alectinib (RG7853) ALK-pos. NSCLC

PD-L1 MAb (RG7446) NSCLC 2nd/3rd line

ipatasertib AKT inh (RG7440) solid tumors

MAO-B inh (RG1577) Alzheimer‘s

polatuzumab vedotin (RG7596)

CD79b ADC heme tumors

LptD antibiotic (RG7929) antibacterial

lebrikizumab (RG3637) idiopathic pulmonary fibrosis

2016

PDL-1 MAb (RG7446) combo Avastin RCC

Flu A MAb (RG7745) influenza

taselisib (PI3Ki, RG7604) (mutant-selective) solid tumors

GABRA5 NAM (RG1662) Down syndrome

lifastuzumab (RG7599)

NaPi2b ADC Pt resistant OC

PDL-1 MAb (RG7446) bladder cancer

CSF-1R MAb (RG7155)

PVNS and solid tumors

venetoclax (Bcl-2i, RG7601) + Gazyva DLBCL

Ang2-VEGF MAb (RG7221)

colorectal cancer

Status as of January 28, 2015

ocrelizumab (RG1594) PPMS

FIXa /FX bispecific MAb (RG6013) hemophilia A

cobimetinib TNBC

venetoclax (Bcl-2i, RG7601) + Gazyva CLL 1st line

venetoclax (Bcl-2i, RG7601) + Rituxan rel/ref FL

venetoclax (Bcl-2i, RG7601) CLL rel/ref

pictilisib PI3K inh (RG7321) solid tumors

SERD (RG6046)

ER+(HER2-neg) mBC

Avastin NSCLC adj

2014 2015 2017 and beyond

Indicates submission to health authorities has occurred.

* approved in EU; ** approved in US

Unless stated otherwise, submissions are planned to occur in US and EU.

Submissions of additional indications for existing

products

Projects currently in phase 2 and 3

36

Actemra systemic sclerosis

Perjeta HER2-pos. BC adj

Perjeta

HER2-pos. gastric cancer 1L

Zelboraf

melanoma adj.

Kadcyla +/- Perjeta

HER2-pos mBC 1st line

Kadcyla

HER2-pos gastric cancer 2L

Kadcyla

HER2-pos. BC adj

**Avastin (EU)

cervical cancer recurrent

Actemra giant cell arteritis

2016

*Avastin (US) rel. ovarian ca. Pt-resist

Avastin (US)

GBM

Gazyva DLBCL 1st line

Gazyva iNHL rituximab refractory

Gazyva follicular lymphoma 1st line

Neuroscience

Ophthalmology

Other

NME

Oncology

Immunology

Infectious Diseases

CardioMetabolism

Perjeta

HER2-pos. mBC 2ndline

Lucentis (US) diabetic retinopathy

**Perjeta (EU) HER2-pos. BC neoadj

MabThera SC (EU) CLL

Status as of January 28, 2015

Avastin +Tarceva(EU)

EGFR mut+ NSCLC

*Avastin (US) ovarian cancer 1st line

*Avastin (US) rel. ovarian ca. Pt-sens

Kadcyla+Perjeta

HER2-pos. BC adj

Kadcyla+Perjeta

HER2-pos. BC neoadj

Kadcyla

HER2-pos. NSCLC

Major granted and pending approvals 2014

37

Neuroscience

Ophthalmology

Other

NME

Oncology

Immunology

Infectious Diseases

CardioMetabolism

EU

US

Approved Pending approvals

MabThera NHL sc formulation

March 2014

RoActemra

RA sc formulation April 2014

Xolair

chronic idiopathic urticaria

March 2014

Avastin

rel. ovarian ca. Pt-resist

August 2014

RoActemra

early RA

September 2014

Gazyvaro

CLL

July 2014

Avastin cervical cancer

Filed April 2014

Avastin cervical cancer

August 2014

alectinib ALECENSA ALK-pos rec/adv NSCLC

July 2014

Zelboraf

m. melanoma December 2014

Japan-Chugai

Perjeta BC neoadjuvant

Filed September 2014

cobimetinib + Zelboraf

m. melanoma

Filed September 2014

Lucentis diabetic retinopathy

Filed August 2014

Esbriet*

idiopathic pulmonary fibrosis

October 2014

Esbriet*

idiopathic pulmonary fibrosis

March 2011

* Newly acquired asset (Intermune) Status as of January 28, 2015

Avastin

rel. ovarian ca. Pt-resist

November 2014

MabThera SC CLL

Filed November 2014

cobimetinib + Zelboraf

m. melanoma

Filed December 2014

38

Doing now what patients need next